Tom McKillop. Show Affiliations »
Abstract
Mesh: See more » Clinical Trials as Topic/statistics & numerical dataDrug Approval/statistics & numerical dataDrug Industry/statistics & numerical dataFluorobenzenes/adverse effectsFluorobenzenes/standardsFluorobenzenes/therapeutic useHumansHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsHydroxymethylglutaryl-CoA Reductase Inhibitors/standardsHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic useHyperlipidemias/drug therapyPeriodicals as Topic/standardsProduct Surveillance, Postmarketing/statistics & numerical dataPyrimidines/adverse effectsPyrimidines/standardsPyrimidines/therapeutic useRosuvastatin CalciumSulfonamides/adverse effectsSulfonamides/standardsSulfonamides/therapeutic useUnited Kingdom
Substances: See more » FluorobenzenesHydroxymethylglutaryl-CoA Reductase InhibitorsPyrimidinesSulfonamidesRosuvastatin Calcium
Year: 2003 PMID: 14602449 DOI: 10.1016/S0140-6736(03)14698-3
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321